Xponance Inc. Purchases 6,310 Shares of Avantor, Inc. (NYSE:AVTR)

Xponance Inc. increased its holdings in shares of Avantor, Inc. (NYSE:AVTR) by 5.9% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 113,456 shares of the company’s stock after purchasing an additional 6,310 shares during the period. Xponance Inc.’s holdings in Avantor were worth $2,391,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. MassMutual Private Wealth & Trust FSB lifted its position in shares of Avantor by 99.5% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock valued at $26,000 after buying an additional 625 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in Avantor by 106.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company’s stock valued at $34,000 after purchasing an additional 830 shares during the last quarter. Global Retirement Partners LLC lifted its holdings in Avantor by 76.7% during the 4th quarter. Global Retirement Partners LLC now owns 2,459 shares of the company’s stock valued at $52,000 after purchasing an additional 1,067 shares during the last quarter. UMB Bank n.a. boosted its position in Avantor by 56.3% during the fourth quarter. UMB Bank n.a. now owns 2,981 shares of the company’s stock worth $63,000 after purchasing an additional 1,074 shares during the period. Finally, AlphaQuest LLC acquired a new position in shares of Avantor in the fourth quarter valued at $65,000. Institutional investors own 95.08% of the company’s stock.

Avantor Stock Up 2.0 %

AVTR stock opened at $16.61 on Friday. The company has a market cap of $11.31 billion, a PE ratio of 15.97, a price-to-earnings-growth ratio of 1.55 and a beta of 1.30. The company has a quick ratio of 0.70, a current ratio of 1.07 and a debt-to-equity ratio of 0.54. Avantor, Inc. has a 52 week low of $15.37 and a 52 week high of $28.00. The business has a 50-day simple moving average of $18.98 and a 200 day simple moving average of $21.74.

Avantor (NYSE:AVTR) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.01. Avantor had a net margin of 10.49% and a return on equity of 12.17%. During the same quarter in the prior year, the firm posted $0.22 earnings per share. Sell-side analysts anticipate that Avantor, Inc. will post 1.06 EPS for the current fiscal year.

Insider Buying and Selling at Avantor

In other news, EVP James Bramwell sold 3,758 shares of the stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $17.53, for a total value of $65,877.74. Following the completion of the transaction, the executive vice president now owns 87,379 shares of the company’s stock, valued at approximately $1,531,753.87. This represents a 4.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Steven W. Eck sold 4,907 shares of Avantor stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $17.53, for a total transaction of $86,019.71. Following the sale, the chief accounting officer now directly owns 40,604 shares in the company, valued at $711,788.12. This trade represents a 10.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.30% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on AVTR shares. Citigroup cut their target price on shares of Avantor from $22.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. UBS Group restated a “neutral” rating and set a $25.00 price objective (down from $29.00) on shares of Avantor in a research report on Friday, January 17th. Raymond James reaffirmed an “outperform” rating and issued a $24.00 target price (down previously from $26.00) on shares of Avantor in a research report on Monday, February 10th. Morgan Stanley dropped their price target on Avantor from $27.00 to $25.00 and set an “overweight” rating for the company in a report on Monday, February 10th. Finally, Stifel Nicolaus decreased their price objective on Avantor from $28.00 to $26.00 and set a “buy” rating on the stock in a report on Monday, February 10th. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, Avantor presently has an average rating of “Moderate Buy” and an average price target of $25.50.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.